A medicine once widely used to treat type 2 diabetes is now facing renewed concerns after a large study found it may raise the risk of dangerous heart problems.
The drug, called rosiglitazone, was developed to help people lower their blood sugar levels and improve the way the body uses insulin. For many years, it was seen as a hopeful treatment for millions of people living with type 2 diabetes, a condition that affects how the body controls sugar in the blood.
Type 2 diabetes is one of the most common long-term health conditions in the world. People with the disease often struggle to keep their blood sugar levels under control.
Over time, high blood sugar can damage the heart, kidneys, eyes, and nerves. Doctors usually recommend healthy eating, exercise, and medicine to help manage the condition. Rosiglitazone belonged to a group of drugs called thiazolidinediones, which work by helping the body respond better to insulin.
Although the medicine was effective at lowering blood sugar, concerns about its safety started to appear years ago. Some earlier studies suggested that people taking the drug might have a higher chance of heart attacks and other cardiovascular problems.
However, the evidence was not always clear because many of the studies were small or used limited data. Scientists and doctors continued to debate whether the medicine was truly dangerous or whether the risks had been overstated.
Now, researchers from the Yale School of Public Health have carried out one of the largest and most detailed reviews ever done on rosiglitazone. Their findings add strong new evidence that the medicine may increase the risk of serious heart-related complications. The study was published in the journal BMJ.
The Yale team examined data from more than 130 clinical trials involving over 48,000 patients. Unlike some earlier research, the scientists were able to look closely at detailed patient information from many different studies.
This allowed them to better compare the health outcomes of people taking rosiglitazone with those taking other diabetes treatments or a placebo.
The results were worrying. According to the study, patients taking rosiglitazone had a 33% higher risk of major cardiovascular events. These included heart attacks, heart failure, and deaths linked to heart problems.
Among 11,837 patients who used the drug, 274 experienced serious cardiovascular issues. In comparison, 219 similar events occurred among 9,319 people in the control groups.
While the difference may not seem very large at first glance, health experts say it is important because millions of people around the world have used diabetes medicines like rosiglitazone. Even a modest increase in risk can affect a large number of patients when a drug is used widely.
Heart health is especially important for people with type 2 diabetes because they already face a higher risk of cardiovascular disease. Diabetes can damage blood vessels and increase the chances of heart attacks and strokes.
For this reason, doctors must carefully consider whether a treatment designed to help diabetes could also create new health dangers.
The new findings help explain why many countries have already restricted the drug. In Europe, rosiglitazone was suspended years ago because of safety concerns. In the United States, strict controls were placed on how the medicine could be prescribed.
The debate over rosiglitazone became one of the biggest examples of concerns about drug safety and the need for careful monitoring after medicines reach the market.
The Yale researchers also highlighted another important issue: transparency in medical research. They stressed that independent scientists should have access to detailed clinical trial data so that medicines can be studied properly.
When researchers can review patient-level data from many trials, they are more likely to identify hidden risks or side effects that smaller studies may miss.
Experts say the case of rosiglitazone shows why long-term safety studies are essential, especially for medicines used by large numbers of people over many years.
A drug may appear helpful at first because it improves one part of health, such as blood sugar levels, but later research may reveal harmful effects in other areas of the body.
Today, diabetes treatment has expanded greatly, with newer medicines available that may offer better protection for both blood sugar control and heart health.
Doctors now often consider cardiovascular safety when choosing treatments for patients with type 2 diabetes. This shift has changed the way diabetes medicines are tested and approved.
The Yale study serves as a reminder that managing diabetes is not only about lowering blood sugar. Patients and doctors must also think about overall health, including the heart. For some people, the benefits of rosiglitazone may not outweigh the risks.
Researchers hope that lessons learned from this drug will improve future drug testing and help protect patients. Careful monitoring, open sharing of research data, and continued scientific studies remain important for making sure medicines are both effective and safe.
If you care about heart health, please read studies about top 10 foods for a healthy heart, and how to eat right for heart rhythm disorders.
For more health information, please see recent studies about how to eat your way to cleaner arteries, and salt and heart health: does less really mean more?
Copyright © 2026 Knowridge Science Report. All rights reserved.
